HBM Partners is a Swiss healthcare investor managing USD 3 billion in assets. The firm focuses on venture, growth, and buy-out financings of private companies, as well as investments in public companies. Their primary sectors include biopharma, medtech, diagnostics, and healthcare in Europe, North America, India, China, and other emerging markets.
HBM Partners advises SIX-listed HBM Healthcare Investments Ltd and other specialized funds. Notable portfolio companies include Hookipa Pharma, iTeos Therapeutics, and Upstream Bio. The firm typically participates in Series B to Series D rounds, with investments ranging from $9 million to $208 million. HBM Partners offers expertise in healthcare investing and is regulated by FINMA, Switzerland's financial market supervisory authority.
HBM Partners - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments25
Current Portfolio Count16
Total Portfolio Exits1
Top Investment Stages
Series B7 (33.3%)
Series C6 (28.6%)
Series D4 (19.0%)
Convertible Note2 (9.5%)
Series A2 (9.5%)
Stage Mix
Series B 33%Series C 29%Series D 19%Convertible Note 10%Series A 10%
Concentration shown as share of disclosed investments by stage.
HBM Partners - Classification
- Also Known As
- HBM Partners AG
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end